Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA clears IDEV Supera Veritas delivery system
Supera Veritas is the delivery system for IDEV’s Supera wire interwoven nitinol stent, currently cleared in the US for palliative treatment of biliary strictures produced by malignant neoplasms.
Supera Veritas is the delivery system for IDEV’s Supera wire interwoven nitinol stent, currently cleared in the US for palliative treatment of biliary strictures produced by malignant neoplasms.
NMT’s product development platform, based on transdermal neuromodulation technology, will be leveraged for a wide variety of emesis indications, including post-operative nausea, cancer treatment, pregnancy and motion sickness,
HepaLife said that its subsidiary, Alliqua BioMedical (Alliqua), recently retained Jeiven Pharmaceutical Consulting (Jeiven) to assist it in this new product development. Through this partnership, Alliqua intends to
Talecris Biotherapeutics claims that Prolastin-C is more concentrated and purified formulation of Prolastin, the only approved alpha1-augmentation therapy in Canada. Prolastin-C and Prolastin are indicated for chronic augmentation
The grant to GTx comprises separate payments of $244,000 for each of five cancer and cancer supportive care research and development programs. Gtx CEO Mitchell Steiner said that
Enzon Pharma has posted a net loss of $8.35m for the third quarter 2010, compared to net income of $133,000 for the comparable period in 2009. The company’s
CeNeRx said that these positive results further confirm the good safety profile demonstrated by TriRima in Phase I studies and set the stage for a Phase II clinical
Pursuant to the stock purchase agreement, Cambrex is expected to acquire the remaining 49% in early 2016 at a value based on a weighted combination of a multiple
Silenor is approved for use in people with chronic (long-term) or transient (short-term) insomnia characterised by difficulty with sleep maintenance. According to Somaxon, Silenor can be used for
OncoMed’s lead candidate, OMP-21M18, is currently in Phase Ib clinical trials. OncoMed’s pipeline also includes several preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed Pharma